Trial · NCT07004712
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
NCT07004712, Phase 2, Not yet recruiting, Peking University Cancer Hospital & Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer. Trials, record NCT07004712. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07004712
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
- NCT number
- NCT07004712
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 46 participants, estimated
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Conditions
- Small Cell Lung Cancer
- Interventions
- Adebelizumab combined with irinotecan liposome as second-line therapy
- First posted
- 2025-06-04
- Last updated
- 2025-06-08
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | 0-12months | It refers to the time from the date when the subjects enter the group to the time when the disease progresses or dies, whichever comes first. |
| Secondary | Percentage of Participants Who Had an Objective Response Rate(ORR) Based on Response Evaluation Criteria In Solid Tumors (RECIST) Criteria. | through study completion, an average of 1 year | the proportion of subjects who achieve CR or PR as the best tumor remission during treatment. |
| Secondary | Overall Survival (OS) | 0-5years | The time from the date of admission to the death caused by any cause. |
| Secondary | Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | through study completion, an average of 2 year | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 |
| Secondary | Biomarker | "Baseline" and "after 2 cycles of treatment" | ScRNA-seq was used to detect the puncture tissue samples before treatment, so as to analyze the influence of single cell level immune signal pathway and immune microenvironment on the efficacy of immunotherapy and explore biomarkers to predict the efficacy. At the same time, the peripheral blood samples were tested by metabonomics before treatment, after 2 cycles of evaluation and when the disease progressed, so as to explore metabolic markers that can predict and dynamically reflect the efficacy of immunotherapy through non-invasive liquid biopsy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07004712
GET https://conductscience.org/api/trials/v1/NCT07004712/registered